276 related articles for article (PubMed ID: 24504055)
1. Propranolol inhibits glucose metabolism and 18F-FDG uptake of breast cancer through posttranscriptional downregulation of hexokinase-2.
Kang F; Ma W; Ma X; Shao Y; Yang W; Chen X; Li L; Wang J
J Nucl Med; 2014 Mar; 55(3):439-45. PubMed ID: 24504055
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase II.
Hamada K; Tomita Y; Qiu Y; Zhang B; Ueda T; Myoui A; Higuchi I; Yoshikawa H; Aozasa K; Hatazawa J
Ann Nucl Med; 2008 Oct; 22(8):699-705. PubMed ID: 18982473
[TBL] [Abstract][Full Text] [Related]
3. Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma.
Paudyal B; Paudyal P; Oriuchi N; Tsushima Y; Nakajima T; Endo K
Int J Oncol; 2008 Nov; 33(5):1047-54. PubMed ID: 18949368
[TBL] [Abstract][Full Text] [Related]
4. Glucose-6-phosphatase Expression-Mediated [
Kim MJ; Lee CH; Lee Y; Youn H; Kang KW; Kwon J; Alavi A; Carlin S; Cheon GJ; Chung JK
Mol Imaging Biol; 2019 Oct; 21(5):917-925. PubMed ID: 30719695
[TBL] [Abstract][Full Text] [Related]
5. Changes in 2-fluoro-2-deoxy-D-glucose incorporation, hexokinase activity and lactate production by breast cancer cells responding to treatment with the anti-HER-2 antibody trastuzumab.
Cheyne RW; Trembleau L; McLaughlin A; Smith TA
Nucl Med Biol; 2011 Apr; 38(3):339-46. PubMed ID: 21492782
[TBL] [Abstract][Full Text] [Related]
6. 2-[18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II.
Ong LC; Jin Y; Song IC; Yu S; Zhang K; Chow PK
Acta Radiol; 2008 Dec; 49(10):1145-53. PubMed ID: 18979289
[TBL] [Abstract][Full Text] [Related]
7. ¹⁸FDG PET for grading malignancy in thymic epithelial tumors: significant differences in ¹⁸FDG uptake and expression of glucose transporter-1 and hexokinase II between low and high-risk tumors: preliminary study.
Nakajo M; Kajiya Y; Tani A; Yoneda S; Shirahama H; Higashi M; Nakajo M
Eur J Radiol; 2012 Jan; 81(1):146-51. PubMed ID: 20810231
[TBL] [Abstract][Full Text] [Related]
8. Biologic correlation between glucose transporters, hexokinase-II, Ki-67 and FDG uptake in malignant melanoma.
Park SG; Lee JH; Lee WA; Han KM
Nucl Med Biol; 2012 Nov; 39(8):1167-72. PubMed ID: 22901702
[TBL] [Abstract][Full Text] [Related]
9. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer.
Higashi T; Saga T; Nakamoto Y; Ishimori T; Mamede MH; Wada M; Doi R; Hosotani R; Imamura M; Konishi J
J Nucl Med; 2002 Feb; 43(2):173-80. PubMed ID: 11850481
[TBL] [Abstract][Full Text] [Related]
10. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor.
Zhao S; Kuge Y; Mochizuki T; Takahashi T; Nakada K; Sato M; Takei T; Tamaki N
J Nucl Med; 2005 Apr; 46(4):675-82. PubMed ID: 15809491
[TBL] [Abstract][Full Text] [Related]
11. Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]-2-fluro-2-deoxy-D-glucose positron emission tomography.
Paudyal B; Oriuchi N; Paudyal P; Higuchi T; Nakajima T; Endo K
Cancer Sci; 2008 Feb; 99(2):260-6. PubMed ID: 18271924
[TBL] [Abstract][Full Text] [Related]
12. Relationship between FDG uptake and expressions of glucose transporter type 1, type 3, and hexokinase-II in Reed-Sternberg cells of Hodgkin lymphoma.
Shim HK; Lee WW; Park SY; Kim H; Kim SE
Oncol Res; 2009; 17(7):331-7. PubMed ID: 19408578
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol suppresses cancer cell glucose uptake by targeting reactive oxygen species-mediated hypoxia-inducible factor-1α activation.
Jung KH; Lee JH; Thien Quach CH; Paik JY; Oh H; Park JW; Lee EJ; Moon SH; Lee KH
J Nucl Med; 2013 Dec; 54(12):2161-7. PubMed ID: 24221993
[TBL] [Abstract][Full Text] [Related]
14. Relationship between glucose transporter, hexokinase and FDG-PET in esophageal cancer.
Tohma T; Okazumi S; Makino H; Cho A; Mochiduki R; Shuto K; Kudo H; Matsubara K; Gunji H; Ochiai T
Hepatogastroenterology; 2005; 52(62):486-90. PubMed ID: 15816463
[TBL] [Abstract][Full Text] [Related]
15. Expression and function of hexose transporters GLUT1, GLUT2, and GLUT5 in breast cancer-effects of hypoxia.
Hamann I; Krys D; Glubrecht D; Bouvet V; Marshall A; Vos L; Mackey JR; Wuest M; Wuest F
FASEB J; 2018 Sep; 32(9):5104-5118. PubMed ID: 29913554
[TBL] [Abstract][Full Text] [Related]
16. Correlation between FDG uptake by PET/CT and the expressions of glucose transporter type 1 and hexokinase II in cervical cancer.
Tong SY; Lee JM; Ki KD; Choi YJ; Seol HJ; Lee SK; Huh CY; Kim GY; Lim SJ
Int J Gynecol Cancer; 2012 May; 22(4):654-8. PubMed ID: 22398711
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET/CT monitoring of β3 agonist-stimulated brown adipocyte recruitment in white adipose tissue.
Park JW; Jung KH; Lee JH; Quach CH; Moon SH; Cho YS; Lee KH
J Nucl Med; 2015 Jan; 56(1):153-8. PubMed ID: 25525187
[TBL] [Abstract][Full Text] [Related]
18. Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy.
Engles JM; Quarless SA; Mambo E; Ishimori T; Cho SY; Wahl RL
J Nucl Med; 2006 Apr; 47(4):603-8. PubMed ID: 16595493
[TBL] [Abstract][Full Text] [Related]
19. Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma.
van Berkel A; Rao JU; Kusters B; Demir T; Visser E; Mensenkamp AR; van der Laak JA; Oosterwijk E; Lenders JW; Sweep FC; Wevers RA; Hermus AR; Langenhuijsen JF; Kunst DP; Pacak K; Gotthardt M; Timmers HJ
J Nucl Med; 2014 Aug; 55(8):1253-9. PubMed ID: 24925884
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological presentation of varying 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma.
Paudyal B; Oriuchi N; Paudyal P; Tsushima Y; Higuchi T; Miyakubo M; Ishikita T; Nakajima T; Endo K
Ann Nucl Med; 2008 Jan; 22(1):83-6. PubMed ID: 18250992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
